Browsing Tag

efgartigimod

Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for…

Eli Pacheco Jun 30, 2023 0

First-and-only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis…

Health

Durable Platelet Response in Immune Thrombocytopenia With Efgartigimod

Eli Pacheco Dec 13, 2022 0

NEW ORLEANS -- An antibody fragment targeting neonatal Fc receptor (FcRn) achieved sustained platelet response in significantly…

Health

FUJIFILM Diosynth Biotechnologies Enters Into an Agreement with Argenx to Manufacture…

Eli Pacheco Oct 27, 2022 0

HILLERØD, Denmark, Oct. 27, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization for biologics, vaccines, and…

Health

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients…

Eli Pacheco Jul 13, 2022 0

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global…

Health

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational…

Eli Pacheco Nov 16, 2021 0

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global…

Health

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational…

Eli Pacheco Nov 11, 2021 0

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), is a patient-focused, innovative, commercial-stage, global…